Effect of Fenofibrate on Uric Acid Metabolism in Japanese Hyperlipidemic Patients

Noguchi, Yoshihiko; Tatsuno, Ichiro; Suyama, Keiko; Shibata, Takahisa; Yoshida, Tomohiko; Otsuka, Yuichiro; Fuse, Masami; Takeo, Chikari; Saitō, Yasushi

doi:10.5551/jat.11.335

Cited by 12 publications

(6 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consistent with the report by Cariou et al [18], γ-GTP positively correlated with PCSK9 at baseline in our study, and thus the significant decrease in γ-GTP only with bezafibrate might be related to the milder increase in circulating PCSK9 levels with bezafibrate than fenofibrate. A significant reduction in uric acid levels by fenofibrate in the present study is consistent with previous report [51], whereas there is no previous report on the effect of bezafibrate treatment on uric acid.…”

Section: Discussionsupporting

confidence: 82%

Comparison of effects of bezafibrate and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 and adipocytokine levels in dyslipidemic subjects with impaired glucose tolerance or type 2 diabetes mellitus: Results from a crossover study

Noguchi¹,

Kobayashi²,

Yagi³

et al. 2011

Atherosclerosis

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 82%

Comparison of effects of bezafibrate and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 and adipocytokine levels in dyslipidemic subjects with impaired glucose tolerance or type 2 diabetes mellitus: Results from a crossover study

Noguchi¹,

Kobayashi²,

Yagi³

et al. 2011

Atherosclerosis

View full text Add to dashboard Cite

show abstract

“…Our study findings showed that serum urate was reduced an additional 23% with fenofibrate therapy. This result is consistent with previous studies on healthy subjects that demonstrated a 23~31% reduction of serum urate after treatment with fenofibrate at six or 12 weeks10, 14). The antihyperuricemic effect of fenofibrate occurred after a relatively short period of time at eight weeks after initiation of fenofibrate treatment; this was reversed after discontinuation of the drug.…”

Section: Discussionsupporting

confidence: 92%

Effect of Fenofibrate in Combination with Urate Lowering Agents in Patients with Gout

Lee

Lee²,

Lee³

2006

Korean J Intern Med

View full text Add to dashboard Cite

BackgroundTo assess the efficacy of fenofibrate treatment in combination with urate lowering agents in patients with gout.MethodsFourteen male patients with chronic tophaceous or recurrent acute attacks of gout were evaluated in an open-label pilot study of the hypolipidemic agent, fenofibrate (Lipidil Supra® 160 mg/d). Patients were stable on urate lowering agents (allopurinol or benzbromarone) for ≥three months without acute attack for the most recent one month before participating. All patients were being treated with established doses of urate lowering agents without modification throughout the study. Clinical and biochemical assessments including serum uric acid, creatinine, liver function test and fasting serum lipid were measured at (1) baseline (2) after two months of fenofibrate treatment and (3) two months after fenofibrate was withdrawn.ResultsSerum uric acid was lowered by 23% after two months of fenofibrate treatment (6.93±2.16 vs. 5.22±1.16 mg/dL; p=0.016). Triglyceride levels were also reduced after fenofibrate treatment (p=0.001). However, this effect was reversed after the withdrawal (p=0.002) of the drug. Alkaline phosphatase was reduced after fenofibrate treatment (p=0.006), but increased 21% after the withdrawal of the drug (p=0.002). By contrast, serum levels of high density lipoprotein and creatinine were increased 9% (p=0.018) and 12% (p=0.006), respectively; however, both levels were significantly decreased to the baseline levels upon withdrawal of fenofibrate.ConclusionsFenofibrate can effectively reduce uric acid levels in addition to its known hypolipidemic effect. Fenofibrate may be used as a potential urate lowering agent in patients with gout, especially in those with coexisting hyperlipidemia.

show abstract

“…More studies on the effect of fenofibrate on uric acid reduction were carried out in patients with hypertriglyceridemia or diabetes 19 , 29 , 30 . In the randomized and controlled fenofibrate intervention and event lowering in diabetes (FIELD) study conducted to determine the effect of fenofibrate on type 2 diabetes, uric acid levels were decreased by 10.3% in 622 patients with diabetes who took allopurinol.…”

Section: Discussionmentioning

confidence: 99%

Effect of fenofibrate on uric acid level in patients with gout

Jung

Choi

Suh

et al. 2018

Sci Rep

View full text Add to dashboard Cite

Gout is a chronic disease associated with deposition of monosodium urate crystals and accompanied by diabetes, hypertension, and dyslipidemia. Hypertriglyceridemia is common among patients with gout, and fenofibrate is usually used to reduce triglyceride levels. The aim of this study is to determine the effect of uric acid reduction by fenofibrate in patients with gout administered uric acid lowering agents (viz., the xanthine oxidase inhibitors allopurinol and febuxostat). Data from 863 patients with gout were collected from electronic medical records comprising information on underlying diseases, laboratory findings, and drug histories. Among all the patients, 70 (8.11%) took fenofibrate with allopurinol or febuxostat. Male and young patients took fenofibrate more frequently, and hypertension was less frequent in patients administered xanthine oxidase inhibitors and fenofibrate than in those administered only xanthine oxidase inhibitors. After the treatment, serum uric acid levels more significantly decreased (−1.81 ± 2.41 vs. −2.40 ± 2.28 mg/dL, p = 0.043) in patients with fenofibrate cotreatment, than in those administered allopurinol or febuxostat alone. The effect of uric acid reduction was larger (b = −1.098, p < 0.001) in patients taking glucocorticoids than in those administered other treatments. There was no difference in the levels of creatinine, blood urea nitrogen, and aminotransferases between patients treated with and without fenofibrate. Fenofibrate additionally reduced uric acid levels without showing any change in the results of renal or liver function tests, suggesting that the addition of fenofibrate is a reasonable option for treating gout in patients having high triglyceride levels.

show abstract

Effect of Fenofibrate on Uric Acid Metabolism in Japanese Hyperlipidemic Patients

Cited by 12 publications

References 33 publications

Comparison of effects of bezafibrate and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 and adipocytokine levels in dyslipidemic subjects with impaired glucose tolerance or type 2 diabetes mellitus: Results from a crossover study

Comparison of effects of bezafibrate and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 and adipocytokine levels in dyslipidemic subjects with impaired glucose tolerance or type 2 diabetes mellitus: Results from a crossover study

Effect of Fenofibrate in Combination with Urate Lowering Agents in Patients with Gout

Effect of fenofibrate on uric acid level in patients with gout

Contact Info

Product

Resources

About